Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

NCT02038842 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

92

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: LIPO-5
BIOLOGICAL: MVA HIV-B (MVATG17401)
BIOLOGICAL: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots

Sponsor

ANRS, Emerging Infectious Diseases